Skip to content

Study · Animal study (in vivo) · c57bl and 6 mice · 2011

11 results

Teriparatide therapy and beta-tricalcium phosphate enhance scaffold reconstruction of mouse femoral defects.

Jacobson JA, Yanoso-Scholl L, Reynolds DG, Dadali T, Bradica G, Bukata S, Puzas EJ, Zuscik MJ, Rosier R, O'Keefe RJ, Schwarz EM, Awad HA

Tissue engineering. Part A29 Oct 2010Cited by 28 (Europe PMC)

PMID20807012 (opens in a new tab)PMCIDPMC3028991 (opens in a new tab)DOI10.1089/ten.tea.2010.0115 (opens in a new tab)PepBankPUB-20807012
Source linkPubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with scaffold-reconstructed femoral defects, teriparatide significantly increased bone volume at 6 weeks versus controls.

    In plain wordsIn mice, teriparatide increased bone volume at 6 weeks versus controls.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone volume at six weeks
    Study

    C57Bl/6 micen: not reported in source

    Scaffold-reconstructed femoral defects
    Comparator
    Saline-treated controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 μg/kg daily · subcutaneousAs given in this study (C57Bl/6 mice).

    Source sentences

    Summary
    Teriparatide treatment increased bone volume and bone mineral content significantly at 6 weeks
    1 context sentence
    Summary · context
    Experimental mice were treated starting at 1 week postop with daily subcutaneous injections of 40 μg/kg teriparatide until sacrifice at 9 weeks, whereas control mice underwent the same procedure but were injected with sterile saline.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with scaffold-reconstructed femoral defects, teriparatide significantly increased bone mineral content at 6 weeks versus controls.

    In plain wordsIn mice, teriparatide increased bone mineral content at 6 weeks versus controls.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone mineral content at six weeks
    Study

    C57Bl/6 micen: not reported in source

    Scaffold-reconstructed femoral defects
    Comparator
    Saline-treated controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 μg/kg daily · subcutaneousAs given in this study (C57Bl/6 mice).

    Source sentences

    Summary
    Teriparatide treatment increased bone volume and bone mineral content significantly at 6 weeks
    1 context sentence
    Summary · context
    Experimental mice were treated starting at 1 week postop with daily subcutaneous injections of 40 μg/kg teriparatide until sacrifice at 9 weeks, whereas control mice underwent the same procedure but were injected with sterile saline.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with scaffold-reconstructed femoral defects, teriparatide enhanced trabeculated callus formation that appeared to surround and integrate with scaffolds.

    In plain wordsIn mice, teriparatide enhanced bone callus formation around the scaffolds.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTrabeculated bone callus formation
    Study

    C57Bl/6 micen: not reported in source

    Scaffold-reconstructed femoral defects
    Comparator
    Saline-treated controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 μg/kg daily · subcutaneousAs given in this study (C57Bl/6 mice).

    Source sentences

    Summary
    led to enhanced trabeculated bone callus formation that appeared to surround and integrate with the scaffold
    1 context sentence
    Summary · context
    Experimental mice were treated starting at 1 week postop with daily subcutaneous injections of 40 μg/kg teriparatide until sacrifice at 9 weeks, whereas control mice underwent the same procedure but were injected with sterile saline.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice, teriparatide treatment established bridging bone union in 30% of reconstructed femurs regardless of scaffold type.

    In plain wordsIn mice, bridging bone union occurred in 30% of teriparatide-treated reconstructed femurs, regardless of scaffold type.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBridging bone union
    Study

    C57Bl/6 micen: not reported in source

    Scaffold-reconstructed femoral defects
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 μg/kg daily · subcutaneousAs given in this study (C57Bl/6 mice).

    Measurements

    Bridging union
    30%
    reconstructed femurs

    Source sentences

    Summary
    thereby establishing union by bridging bone regeneration across the segmental defect in 30% of the reconstructed femurs, regardless of the scaffold type.
    1 context sentence
    Summary · context
    Experimental mice were treated starting at 1 week postop with daily subcutaneous injections of 40 μg/kg teriparatide until sacrifice at 9 weeks, whereas control mice underwent the same procedure but were injected with sterile saline.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice with PLA scaffolds, bone volume during teriparatide treatment declined to control levels at 9 weeks.

    In plain wordsIn mice with PLA scaffolds, bone volume during teriparatide treatment declined to control levels at 9 weeks.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changePLA bone volume at nine weeks
    Study

    C57Bl/6 micen: not reported in source

    Scaffold-reconstructed femoral defects
    Comparator
    Saline-treated controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 μg/kg daily · subcutaneousAs given in this study (C57Bl/6 mice).

    Source sentences

    Summary
    However, the bone volume and mineral content in the PLA reconstructed femurs treated with teriparatide was reduced at 9 weeks to control levels, but remained significantly increased in the PLA/βTCP scaffolds.
    1 context sentence
    Summary · context
    Experimental mice were treated starting at 1 week postop with daily subcutaneous injections of 40 μg/kg teriparatide until sacrifice at 9 weeks, whereas control mice underwent the same procedure but were injected with sterile saline.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In mice with PLA scaffolds, bone mineral content during teriparatide treatment declined to control levels at 9 weeks.

    In plain wordsIn mice with PLA scaffolds, bone mineral content during teriparatide treatment declined to control levels at 9 weeks.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changePLA bone mineral content at nine weeks
    Study

    C57Bl/6 micen: not reported in source

    Scaffold-reconstructed femoral defects
    Comparator
    Saline-treated controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 μg/kg daily · subcutaneousAs given in this study (C57Bl/6 mice).

    Source sentences

    Summary
    However, the bone volume and mineral content in the PLA reconstructed femurs treated with teriparatide was reduced at 9 weeks to control levels, but remained significantly increased in the PLA/βTCP scaffolds.
    1 context sentence
    Summary · context
    Experimental mice were treated starting at 1 week postop with daily subcutaneous injections of 40 μg/kg teriparatide until sacrifice at 9 weeks, whereas control mice underwent the same procedure but were injected with sterile saline.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In mice with PLA/βTCP scaffolds, teriparatide-treated bone volume remained significantly above control levels at 9 weeks.

    In plain wordsIn mice with PLA/βTCP scaffolds, bone volume remained higher with teriparatide than controls at 9 weeks.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasePLA/βTCP bone volume at nine weeks
    Study

    C57Bl/6 micen: not reported in source

    Scaffold-reconstructed femoral defects
    Comparator
    Saline-treated controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 μg/kg daily · subcutaneousAs given in this study (C57Bl/6 mice).

    Source sentences

    Summary
    However, the bone volume and mineral content in the PLA reconstructed femurs treated with teriparatide was reduced at 9 weeks to control levels, but remained significantly increased in the PLA/βTCP scaffolds.
    1 context sentence
    Summary · context
    Experimental mice were treated starting at 1 week postop with daily subcutaneous injections of 40 μg/kg teriparatide until sacrifice at 9 weeks, whereas control mice underwent the same procedure but were injected with sterile saline.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In mice with PLA/βTCP scaffolds, teriparatide-treated bone mineral content remained significantly above control levels at 9 weeks.

    In plain wordsIn mice with PLA/βTCP scaffolds, bone mineral content remained higher with teriparatide than controls at 9 weeks.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasePLA/βTCP bone mineral content at nine weeks
    Study

    C57Bl/6 micen: not reported in source

    Scaffold-reconstructed femoral defects
    Comparator
    Saline-treated controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 μg/kg daily · subcutaneousAs given in this study (C57Bl/6 mice).

    Source sentences

    Summary
    However, the bone volume and mineral content in the PLA reconstructed femurs treated with teriparatide was reduced at 9 weeks to control levels, but remained significantly increased in the PLA/βTCP scaffolds.
    1 context sentence
    Summary · context
    Experimental mice were treated starting at 1 week postop with daily subcutaneous injections of 40 μg/kg teriparatide until sacrifice at 9 weeks, whereas control mice underwent the same procedure but were injected with sterile saline.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In mice, bridged teriparatide-treated femurs showed prototypical brittle bone torsion behavior.

    In plain wordsIn mice, bridged teriparatide-treated femurs showed brittle behavior during twisting tests.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableBrittle torsion behavior
    Study

    C57Bl/6 micen: not reported in source

    Scaffold-reconstructed femoral defects
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 μg/kg daily · subcutaneousAs given in this study (C57Bl/6 mice).

    Source sentences

    Summary
    Further, bridged teriparatide-treated femurs demonstrated a prototypical brittle bone torsion behavior, and were significantly stronger and stiffer than control specimens or treated specimens that failed to form bridging bone union.
    1 context sentence
    Summary · context
    Experimental mice were treated starting at 1 week postop with daily subcutaneous injections of 40 μg/kg teriparatide until sacrifice at 9 weeks, whereas control mice underwent the same procedure but were injected with sterile saline.

Studies that did not test the peptide alone2

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 10AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome

    In mice, bridged teriparatide-treated femurs were stronger than controls or treated specimens without bridging union.

    In plain wordsIn mice, bridged teriparatide-treated femurs were stronger than controls or treated femurs without bridging union.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTorsional strength of bridged femurs
    Study

    C57Bl/6 micen: not reported in source

    Scaffold-reconstructed femoral defects
    Comparator
    Controls or treated femurs without bridging union
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Further, bridged teriparatide-treated femurs demonstrated a prototypical brittle bone torsion behavior, and were significantly stronger and stiffer than control specimens or treated specimens that failed to form bridging bone union.
    1 context sentence
    Summary · context
    Experimental mice were treated starting at 1 week postop with daily subcutaneous injections of 40 μg/kg teriparatide until sacrifice at 9 weeks, whereas control mice underwent the same procedure but were injected with sterile saline.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 11AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome

    In mice, bridged teriparatide-treated femurs were stiffer than controls or treated specimens without bridging union.

    In plain wordsIn mice, bridged teriparatide-treated femurs were stiffer than controls or treated femurs without bridging union.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTorsional stiffness of bridged femurs
    Study

    C57Bl/6 micen: not reported in source

    Scaffold-reconstructed femoral defects
    Comparator
    Controls or treated femurs without bridging union
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Further, bridged teriparatide-treated femurs demonstrated a prototypical brittle bone torsion behavior, and were significantly stronger and stiffer than control specimens or treated specimens that failed to form bridging bone union.
    1 context sentence
    Summary · context
    Experimental mice were treated starting at 1 week postop with daily subcutaneous injections of 40 μg/kg teriparatide until sacrifice at 9 weeks, whereas control mice underwent the same procedure but were injected with sterile saline.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.